Abstract | OBJECTIVES: METHODS: SHRSP were divided into five groups, and were given vehicle, benidipine at 1 or 3 mg/kg per day, or cilnidipine at 1 or 3 mg/kg per day for 7 weeks, and the protective effects against cardiorenal injury were compared among each group. RESULTS:
Benidipine and cilnidipine at the same doses exerted comparable hypotensive effects on SHRSP throughout the treatment. Despite equihypotensive effects between both drugs, benidipine prevented cardiac hypertrophy, fibrosis, and inflammation to a greater extent than cilnidipine. Moreover, benidipine prevented glomerulosclerosis, tubulointerstitial injury, and renal inflammation more than cilnidipine. To elucidate the underlying mechanism of more beneficial effects of benidipine than cilnidipine, we compared the effects of these drugs on cardiac and renal oxidative stress, and aldosterone in SHRSP. Benidipine reduced both cardiac and renal NADPH oxidase activities in SHRSP more than cilnidipine, being associated with more attenuation of cardiac and renal superoxide by benidipine. Furthermore, serum aldosterone was significantly reduced by benidipine but not by cilnidipine. CONCLUSION:
|
Authors | Eiichiro Yamamoto, Keiichiro Kataoka, Yi-Fei Dong, Taishi Nakamura, Masaya Fukuda, Hisato Nako, Hisao Ogawa, Shokei Kim-Mitsuyama |
Journal | Journal of hypertension
(J Hypertens)
Vol. 28
Issue 6
Pg. 1321-9
(Jun 2010)
ISSN: 1473-5598 [Electronic] England |
PMID | 20224431
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Calcium Channel Blockers
- Dihydropyridines
- benidipine
|
Topics |
- Animals
- Blood Pressure
- Calcium Channel Blockers
(pharmacology, therapeutic use)
- Dihydropyridines
(pharmacology, therapeutic use)
- Enzyme-Linked Immunosorbent Assay
- Heart
(drug effects)
- Heart Rate
- Hypertension
(complications)
- Kidney
(drug effects)
- Male
- Rats
- Rats, Inbred SHR
- Rats, Inbred WKY
|